en

Sign up
Investments involve risks and are not suitable for all investors.

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・CRISPR Therapeutics AG
Search

CRISPR Therapeutics AG

Closed

Sector Healthcare

44.58 -1.26

Buy

Price update 6 Sept 2024, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

44.34

Max

44.68

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+65.84 upside

Dividends

By Dow Jones

Next Earnings

1 Nov 2024

News Sentiment

By Acuity

50%

50%

114 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

44.04 / 48.31 Support & Resistance

CRISPR Therapeutics AG Chart

Related News

8 Dec 2023, 20:56 UTC

Major Market Movers

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

DJ

Read

1 Nov 2023, 10:14 UTC

Major Market Movers

Crispr Therapeutics Shares Rally Premarket After Favorable FDA Panel Meeting

DJ

Read

11 Apr 2024, 14:46 UTC

Acquisitions, Mergers, Takeovers

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

DJ

Read

8 Dec 2023, 18:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

DJ

Read

8 Dec 2023, 16:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

DJ

Read

8 Dec 2023, 16:21 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- WSJ

DJ

Read

24 Nov 2023, 12:00 UTC

Top News

Gene Editing Will Change Medicine -- and Maybe Health Investing Too -- Heard on the Street -- WSJ

DJ

Read

Peer Comparison

Price change

CRISPR Therapeutics AG Forecast

Price Target

By TipRanks

65.84% upside

12 Months Forecast

Average 74 USD  65.84%

High 105 USD

Low 30 USD

Based on 18 Wall Street analysts offering 12 month price targets forCRISPR Therapeutics AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

10

Buy

6

Hold

2

Sell

Based on 18 analysts giving stock ratings to CRISPR Therapeutics AG - Dist in the past 3 months.

Technical Score

By Trading Central

44.04 / 48.31Support & Resistance

Short Term

Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Bearish Evidence

All events are bearish.

Long Term

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

114 / 365 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Other stocks from the sector

LLY

Eli Lilly and Co.

902.74

↓-0.9%

UNH

UnitedHealth Group Inc

596.8

↑ +0.31%

NVO

Novo Nordisk A-S

131.05

↑ +0.18%

JNJ

Johnson and Johnson

164.37

↓-0.29%

ABBV

AbbVie Inc

193.18

↑ +0.34%